CURRENT NEWS

• 14.12.2018
• 13.12.2018
  AMAG Pharmaceuticals Enters into Definitive Merger Agreement to Acquire Perosphere Pharmaceuticals
• 13.12.2018
  Orchard Therapeutics Announces the Build-Out of New Gene Therapy Manufacturing Facility in California
• 13.12.2018
  Altimmune Announces Clinical Program Updates and Plans for Pipeline Expansion
• 13.12.2018
  Rhythm Pharmaceuticals Announces First Patient Enrolled in Pivotal Phase 3 Clinical Trial Evaluating Setmelanotide in Bardet-Biedl and AlströM Syndromes
• 13.12.2018
  Avinger Announces Successful Treatment of 500th Patient with Next-Generation Pantheris Device
• 13.12.2018
  Sanofi's Formulation Patents on Multibillion-Dollar Lantus are Invalidated by U.S. Patent and Trademark Office via IPR, Announces Mylan
• 13.12.2018
  Protagonist Therapeutics Initiates Phase 1 Trial of Oral, Gut-Restricted, Alpha-4-Beta-7 Integrin Antagonist PN-10943
• 13.12.2018
  Bruker and Mestrelab Announce Strategic Collaboration and Partnership for Chemistry and Pharma Software Applications
• 13.12.2018
  Check-Cap Announces FDA Conditional Approval of IDE to Initiate U.S. Pilot Study of C-Scan
• 13.12.2018
  Boehringer Ingelheim and Lilly Partner with Duke Clinical Research Institute to Advance Multidisciplinary Care for People with Type 2 Diabetes and Cardiovascular Disease
• 13.12.2018
  XBiotech Announces Publication of Post-Hoc Analysis for Phase III Colorectal Cancer Study
• 13.12.2018
  Health Canada Grants Market Authorization for ORKAMBI (Lumacaftor/Ivacaftor) for Children with Cystic Fibrosis Aged 2 to 5 Years Old with Most Common Form of the Disease
• 13.12.2018
  Sunovion and PsychoGenics Announce Positive Results from Pivotal Phase 2 Study of Novel Investigational Agent SEP-363856 for the Treatment of Schizophrenia
• 13.12.2018
  MabVax Therapeutics Engages Objective Capital as Advisor for Exploring Asset Sales
• 13.12.2018
  Biomax Informatics Launches the NeuroXM Brain Science Suite
• 13.12.2018
  Generex Biotechnology Partner Olaregen Therapeutix Sponsors Annual Meeting of Innovations in Wound Healing
• 13.12.2018
  Innovent Announces Two Clinical Studies with the Anti-VEGF Monoclonal Antibody IBI305, a Biosimilar Candidate to Avastin (Bevacizumab), Met Primary Endpoints
• 13.12.2018
  Pharmaxis Announces First Sales of Aridol in USA
• 13.12.2018
  Aethlon Announces Appointment of Timothy Rodell as Interim Chief Executive Officer

Records per page:

Page

Total: 36104 records.